Accrued Expenses and Other Current Liabilities

6 Months Ended

Jun. 30, 2024

Payables and Accruals [Abstract]

Accrued Expenses and Other Current Liabilities

7. Accrued Expenses and Other Current Liabilities

Accrued expenses and other current liabilities consisted of the following (in thousands):

	June 30, 2024		December 31, 2023
Clinical and development costs	$	1,132	$	1,404
Manufacturing and quality costs		30,448		31,917
Payroll and payroll-related costs		7,437		16,465
Collaboration payable - related party (Note 17)		43,075		28,053
Facility and other		4,264		2,772
	$	86,356	$	80,611

As of June 30, 2024 and December 31, 2023, the Company accrued a total of $28,138 and $30,049, respectively, payable to Bacthera upon the substantial completion of a dedicated production suite for long-term supply of VOWST. This amount is included in the Manufacturing and quality costs category above. This liability is expected to be settled by SPN concurrent with the Closing of the Transaction, as the manufacturing agreement between the Company and Bacthera is being assigned and terminated as part of the Transaction. Pursuant to the termination of the Bacthera manufacturing agreement, SPN will pay a termination payment to Bacthera in full and final settlement of all outstanding liabilities owed to Bacthera.

Additionally, included within payroll and payroll-related costs as of June 30, 2024 and December 31, 2023 is $359 and $5,080, respectively, of accrued severance related to the Company’s restructuring plan. See Note 12, Restructuring, for further details.